Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
YES
DIRECT
TILs recognize the tumor antigenic peptide–HLA-C complex via native TCRs and kill target cells through cytotoxic T-cell effector mechanisms (perforin/granzyme and Fas–FasL), with proinflammatory cytokines aiding apoptosis.
Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
YES
DIRECT
TILs with native TCRs recognize the tumor antigenic peptide–HLA-DR (class II pMHC) on target cells and directly kill them via perforin/granzyme release and/or Fas–FasL–mediated apoptosis.
Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
YES
DIRECT
TILs recognize the tumor antigenic peptide–HLA-DQ complex via their native TCRs and directly kill the bound cell through perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis).
Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
YES
DIRECT
TILs recognize the tumor peptide–HLA-DP complex via native TCRs and directly kill the presenting cell through perforin/granzyme release and Fas–FasL–mediated apoptosis.
Monoclonal antibody against CD20 that depletes pre-B and mature B cells to reduce ANCA production.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing ANCA production.
YES
DIRECT
Binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated effector killing (ADCC/ADCP), with additional apoptosis upon crosslinking.